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INTRODUCTION 
 
Chronic obstructive pulmonary disease (COPD) is the sixth leading cause of morbidity and mortality in the 
western world and the prevalence of the disease is increasing as the population ages [1]. Cigarette smoking is the 
major environmental contributor to the disease in western societies yet only, 15% of cigarette smokers develop the 
disease, indicating that genetic factors play a part in determining susceptibility. Although cigarette smoking is 
considered the major environmental risk factor for the development of COPD, only 20–30% of chronic smokers 
develop severe impairment of lung function associated with this pathogenesis [2]. These individual differences in 
susceptibility to tobacco smoke injury may be related to genetic factors. During the last three decades, research 
studies reported that the imbalance of the protease–antiprotease and the oxidant–antioxidant systems is the major 
factor causing emphysema and COPD [3]. With the notable exception of severe α1-antitrypsin (α1-AT) 
deficiency, these genetic factors are poorly understood. Given that .95% of those who develop COPD are smokers 
and oxidative stress is thought to be important in the pathogenesis of the disease, genetic variation in enzymes that 
protect the lung against smoke-induced oxidative stress has been a significant focus of study. Microsomal epoxide 
hydrolase (EPHX1), an enzyme involved in the first-pass metabolism of epoxide intermediates, has received 
particular attention as two functional variants of the gene, which confer slow and fast metabolic activity, have 
been identified [4]. In order to replicate a subset of these previous genetic associations in COPD, a case–control 
study was performed in 492 Caucasian current or former smokers with and without COPD. The current authors 
chose single nucleotide polymorphisms (SNPs) in three relatively well-studied interesting candidate genes: tumor 
necrosis factor (TNF-α), b2-adrenoreceptor (ADRB2) and microsomal epoxide hydroxylase (EPHX1). A 
 
The purpose of this study was to examine investigation the role of mEPXH1 (His139Arg) polymorphisms 
on number of exacerbations and disease severity in chronic obstructive pulmonary disease in a smoker 
population. Chronic obstructive pulmonary disease (COPD) has become the fourth most common single 
cause of morbidity, and its prevalence is increasing worldwide. It is a syndrome composed of chronic 
bronchitis, small airways disease (bronchiolitis), and emphysema, in varying proportions between 
affected individuals. The study was performed cohort and prospectively. The population consist of 213 
patients with COPD disease. Genotyping of mEPXH1 was performed using multiplex PCR. Data analysis 
included, Pearson’s r correlations, regression analysis, ANOVA analyses, Tukey, test for comparison and 
SPSS software (package of Spss / pc + + ver18). The results showed that there is not relationship 
between polymorphisms of mEPXH1 and number of exacerbations. According the results, there is not 
significant relationship between polymorphisms of mEPXH1 and disease severity. Also there is not 
significant relationship between mEPXH1 and disease in COPD patients on basis parameters of 
spirometery and oxidative stress in COPD patients. 
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systematic literature review and meta-analysis of previous studies was also performed Tyr113His polymorphism 
with a recessive odds ratio (OR) of 3.5 [5], whereas subsequent studies failed to confirm this [6]. The aim of this 
study was to examine investigation the role of mEPXH1 (His139Arg) polymorphisms on number of exacerbations 
and disease severity in chronic obstructive pulmonary disease in a smoker population. 
 
MATERIALS AND METHODS 
 
The study was performed cohort and prospectively. The population consist of 213 patients with COPD disease. In this study, 
patients candidate for COPD were selected in Beasat Clinic of Kerman in Iran. Inclusion criteria for COPD were chronic airway 
symptoms and signs such as coughing, breathlessness, wheezing, and chronic airway obstruction. COPD phenotype 
identification was based on chest radiographic and high-resolution computerized tomography density findings. 
 
DNA preparation 
 
For genotyping, 10 ml blood was drawn into an EDTA tube and stored at -20 C until DNA extraction was carried out. Genomic 
DNA was isolated from whole peripheral blood using the Salting out [7]. 
 
mEPXH1 Genotyping 
 
mEPXH1 (His139Arg) polymorphism was detrmined as descripbed before by authors [8]. To examine the polymorphism of 
mEPXH1 a simultaneous amplification of genes of interest in the same reaction was performed using a multiplex polymerase 
chain reaction (PCR) as described in the literature [9,10,11]. 
 
                     Table: 1. The profile sequences and position-specific of primers mEPHX1 
 
Primer Sequence GC% Tm (°C) Band size 
Forward Common 5’-TGG CAG GAC TCA ATA TCT AGG CTC TG-3’ 50 67.9  
240 bp Reverse Wild 5’-ATC AGC AAG GGC TTC GGG GTA T-3’ 54.5 64 
Reverse Mutant 5’-ATC AGC AAG GGC TTC GGG GTA C-3’ 59.1 65 
 
Statistical analysis 
 
Data analysis included, pearson’s r correlations, regression analysis, ANOVA analyses, Tukey, test for comparsion and SPSS 
software (package of Spss / pc + + ver18). 
 
Demographics results 
 
(1) Of the 213 patients enrolled in the study 162 were smoker and 51 were Nonsmoker (male:female ratio 163:50)  
(2) The education level of 213 subjects were studied, 109 cases were lack education and 104 cases were Educated. 
  
Determination mEPXH1 genotypes (Exon 4) 
 
Figure- 1 shows different genotypes of mEPXH1 after the Multiplex PCR. Despite the band with primers forward common and 
Reverse G indicative GG genotype (Homozygote). Despite the band with primers forward common and Reverse A indicative AA 
genotype (Wild type) and band with primers Forward common, Reverse G and Reverse A indicative GA genotype (Heterozygote). 
 
 
 Fig: 1. The various genotypes of His139Arg polymorphisms (mEPXH1 gen) in Agarose gel 
……………………………………………………………………………………………………………………………………….. 
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Table: 2. Determination various genotype of His139Arg polymorphisms (mEPXH1 gen) 
 
Genotype Band Fragment (bp) Phenotype (Gene expression) 
GG (Homozygot) 240 (only G) High 
AG (Heterozygot) 240 (Both A ,G) Intermediate 
AA (Wild type) 240 (only A) Low 
 
RESULTS 
 
Relationship between polymorphisms of His139Arg (mEPXH1 gen Exon 4) and number of       
exacerbations in COPD patients 
 
Table- 3 shows the results relationship between polymorphisms of His139Arg (mEPXH1 gen Exon 4) and number of 
exacerbations in COPD patients. There is not significant relationship between polymorphisms of His139Arg and number of 
exacerbations in COPD patients. 
 
Table: 3. The relationship between polymorphisms of His139Arg and number of exacerbations in COPD 
patients 
 
        mEPXH1 exon-4 genotype  
Exacerbation/yr. Frequency His/His   His/Arg          Arg/Arg P-value 
No n (%) 48 (47) 42(41) 13(12) 
0.857 1-2 n (%) 30(45) 29(43) 8(12) 
3-4 n (%) 23(54) 14(32) 6(14) 
 
 
 
Fig: 2. The relationship between polymorphisms of His139Arg and number of exacerbations in COPD patients 
………………………………………………………………………………………………………………………………………………………………… 
 
Relationship between polymorphisms of His139Arg (mEPXH1 gen Exon 4) and disease 
severity in COPD patients 
 
Table 4 shows the results relationship between polymorphisms of His139Arg (mEPXH1 gen Exon 4) and disease severity in 
COPD patients. There is not significant relationship between polymorphisms of His139Arg and disease severity in COPD 
patients. 
 
Table: 4. The relationship between polymorphisms of His139Arg and disease severity in COPD patients 
 
mEPXH1 exon-4 
genotype 
FEV1<50 
n(%) 
FEV1>50 
n(%) 
OR 
(95% C.I) 
 
P-value 
His/His 50(46) 51(49) - 
ns 
His/Arg 46(43) 39(37) 
0.8 
(0.5-1.5) 
Arg/Arg 12(11) 15(14) 
1.2 
(0.2-2.9) 
                                                                                                           ns : Non-significant 
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Fig: 3. The relationship between polymorphisms of His139Arg and disease severity in COPD patients 
………………………………………………………………………………………………………………………………………………………………… 
 
Relationship between polymorphisms of His139Arg (mEPXH1 gen Exon 4) and disease 
severity in presence of confounding factors in COPD patients  
 
Table- 5 shows the results relationship between polymorphisms of His139Arg (mEPXH1 gen Exon 4) and disease severity in 
COPD patients in presence of confounding factors (sex, age, smoking and BMI). There is not significant relationship between 
polymorphisms of His139Arg and disease severity in presence of confounding factors in COPD patients. 
 
Table: 5. The relationship between polymorphisms of His139Arg 
(mEPXH1 gen Exon 4) and disease severity in presence of 
confounding factors in COPD patients. 
Variable B P-value OR (95% CI) 
mEPXH 1 Exon4 genotype    
His/His  0.592  
His/Arg -0.122 0.686 0.8 (0.5-1.6) 
Arg/Arg 0.341 0.447 1.4 (0.6-3.4) 
Sex -0.594 0.135 0.5 (0.3-1.2) 
Age -0.001 0.92 0.99 (0.98-1.02) 
Smoking Status 0.056 0.784 1.06 (0.71-1.58) 
BMI 0.042 0.194 1.04 (0.98-1.11) 
 
 
 
Relationship between polymorphisms of His139Arg (mEPXH1 gen Exon 4) and disease 
severity in COPD patients on basis parameters of gender 
 
Table -6 shows the results relationship between polymorphisms of His139Arg (mEPXH1 gen Exon 4) and disease severity in 
COPD patients on the basis parameters of gender. There is not significant relationship between polymorphisms of His139Arg and 
disease severity in COPD patients.  But there is a protective effect against the disease, so that men with genotype AA low (Arg / 
Arg) show the severity high of the disease. 
 
Table: 6. The relationship between polymorphisms of His139Arg (mEPXH1 gen 
Exon 4) and disease severity in COPD patients on basis parameters of gender 
 
        mEPXH1 exon-4 genotype  
Sex COPD 
Stage 
 
His/His 
 
His/Arg         Arg/Arg   
 
OR 
Male 
n (%) 40(51) 32(41) 6(8) 
2.0 
n (%) 44(52) 29(34) 12(14) 
Female 
n (%) 10(33) 14(47) 6(20) 0.2 
n (%) 7(35) 10(50) 3(15) 
                                                                       OR : Odd Ratio 
SPECIAL ISSUE (ARBS)  
_______________________________________________________________________________________________________________________  
       
  
| Mandegary et al. 2016| IIOABJ | Vol. 7 | 8 | 16–22 20 
                           w
w
w
.iio
a
b
.o
rg
                                                                                        
 
   
                                            w
w
w
.iio
a
b
.w
e
b
s
.c
o
m
 
A
P
P
L
. 
 R
E
S
. 
IN
 B
IO
L
. 
 S
C
I.
 
 
Fig: 4. The relationship between polymorphisms of His139Arg (mEPXH1 gen Exon 4) and disease severity in COPD 
patients on basis parameter Male 
………………………………………………………………………………………………………………………………………………………………… 
       
Fig: 5. The relationship between polymorphisms of His139Arg (mEPXH1 gen Exon 4) and disease severity in COPD patients 
on basis parameter Female 
………………………………………………………………………………………………………………………………………………………………… 
 
Relationship between polymorphisms of His139Arg (mEPXH1 gen Exon 4) and disease in 
COPD patients on basis parameters of spirometery 
 
Table- 7 shows the results relationship between polymorphisms of His139Arg (mEPXH1 gen Exon 4) and disease in COPD 
patients on basis parameters of spirometery (FEV1 ،FEV1/FVC and FEF25-75). There is not significant relationship between 
polymorphisms of His139Arg and disease in COPD patients on basis parameters of spirometery. 
 
Table: 7. The relationship between polymorphisms of His139Arg (mEPXH1 gen Exon 4) and disease in 
COPD patients on basis parameters of spirometery 
 
mEPXH1 exon-4 genotype  N Mean (95% CI) P- value 
 
FEV1 
Wilde 101 49.0(45.4-52.5) - 
Hetro 85 50.7(46.9-54.4) ns. 
Mutant 27 51.0(43.2-58.8) ns. 
 
FEV1/FVC 
Wilde 101 73.5(71.6-75.3) - 
Hetro 85 74.0(71.8-76.2) ns. 
Mutant 27 76.6(73.2-79.9) ns. 
 
FEF25-75 
Wilde 100 37.5(32.2-42.7) - 
Hetro 85 39.0(34.1-43.8) ns. 
Mutant 26 38.6(30.8-46.3) ns. 
                                                         FEV1: Forced Expiratory Volume in first second.   FVC: Forced Vital Capacity 
                                                          FEF25-75%: Mean forced Expiratory Flow during the middle half of FVC 
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Relationship between polymorphisms of His139Arg (mEPXH1 gen Exon 4) and disease in 
COPD patients on basis parameters of oxidative stress 
 
Table- 8 shows the results relationship between polymorphisms of His139Arg (mEPXH1 gen Exon 4) and disease in COPD 
patients on basis parameters of oxidative stress (LPO ،SOD   و TAC). There is not significant relationship between polymorphisms 
of His139Arg and disease in COPD patients on basis parameters of oxidative stress. 
 
Table: 8. The relationship between polymorphisms of His139Arg (mEPXH1 gen Exon 4) and disease in 
COPD patients on the basis parameters of oxidative stress 
 
mEPXH1 exon-4 genotype  N Mean (95% CI) P- value 
 
LPO 
Wilde 101 0.2(0.15-0.23) - 
Hetro 85 0.2(0.12-0.20) ns. 
Mutant 26 0.2(0.13-0.27) ns. 
 
SOD 
Wilde 60 2.6(2.50-2.76) - 
Hetro 45 2.7(2.57-2.85) ns. 
Mutant 18 2.7(2.45-2.88) ns. 
 
TAC 
Wilde 101 1.4(1.35-1.50) - 
Hetro 85 1.4(1.32-1.50) ns. 
Mutant 26 1.4(1.25-1.57) ns. 
                                                                                      LPO: Lipid peroxidation        SOD: Superoxide dismutase           TAC: Total antioxidant capacity 
 
 
DISCUSSION 
The purpose of this study was investigation the role of mEPXH1 (His139Arg) polymorphism on number of 
exacerbations and disease severity in chronic obstructive pulmonary disease in a smoker population. Of the 213 
patients enrolled in the study 163 were male and 50 were female. The frequency of different genotypes mEPXH1 
(His139Arg) was including 47.4 % of His/His, 40 %, His/Arg and 12.7% Arg/Arg. Erkisi et al (2010) reported in 
Turkey the abundance of His/His 53.7%, His/Arg 39% and Arg/Arg 7.3% [12]. Cheng et al (2004) reports the 
abundance of His/His 65.6%, His/Arg 31.3% and Arg/Arg 3.3% [9]. The results of this study show the there is not 
significant relationship between polymorphisms of His139Arg and number of exacerbations in COPD patients. 
According the results, there is not significant relationship between Heterozygote genotype and FEV1 <50 (OR= 
0.83; 95%CI: 0.77-1.5) and homozygous genotypes and FEV1 <50 (OR= 1.2; 95%CI: 0.22-2.9) in COPD 
patients. The results of this study show the there is not significant relationship between polymorphisms of 
His139Arg and disease in COPD patients on basis parameters of spirometery (FEV1 ،FEV1/FVC and FEF25-75) and 
oxidative stress (LPO ،SOD   و TAC). These results are in compliant with result Cheng et al (2004), Smith and 
Harrison (1997) and Park (2007) [9, 13, 14]. Cheng et al reported the there is not significant relationship between 
polymorphisms of mEPXH1 His139Arg and risk of COPD in COPD patients ((OR His/Arg= 0.6; 95%CI: 0.3-1.1) 
and (OR Arg/Arg=0.4; 95%CI: 0.1-2.6)) [9]. Sandford et al (2001) indicated the there is significant relationship 
between combining two polymorphisms mEPXH1 His139Arg, His113Tyr and reduced lung function in COPD 
patients on basis parameters of spirometery [15]. Yoshikawa et al (2000) finding the there is significant 
relationship between polymorphisms of His113Tyr and disease severity in COPD patients (OR=2.9; 95%CI: 1.1-
7.4, p=0.025) [16]. Hu et al (2008) reported the there is significant relationship between Homozygous mEPXH1 
and increased risk of COPD disease [17]. Although in some studies shown relationship between polymorphisms 
mEPXH1 (His139Arg) and COPD disease, but in this study there is not significant relationship between 
polymorphisms of His113Tyr and number of exacerbations, disease severity and susceptibility to disease in 
COPD patients. 
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